PreciseDx
New York, US · Founded 2020 · Delaware corporation · 6 known investors
Find your way into PreciseDx
184 people in our graph share verified history with the PreciseDx team — schools, employers, funds. One of them is your warm intro.
Sumant Mandalunlockedknows Eric Converse · together at Michigan State University (overlapped)
×4knows the team · via Michigan State University
×7knows the team · via University of Miami
PreciseDx develops molecular pathology diagnostic tools for cancer care, combining anatomical pathology with molecular and systems biology to enable precise diagnosis and treatment planning. The company's flagship product serves pathologists and oncologists seeking data-driven insights for patient risk stratification and personalized cancer care.
Founders & leadership
PreciseDx was founded in 2020 by Dr. Carlos Cordon-Cardo.
DC
Dr. Carlos Cordon-CardoFounder
EC
Eric ConverseinFounding Board Member - Former Interim ChairHe has previously served as CEO and board member for medical device and healthcare technology companies, and held roles in investment management representing investor interests across multiple funds.
EJ
Edward Joseph SitarChief Financial Officer
WB
Wayne BrinsterinPresident and CEO2021–2024He previously served as CEO at multiple healthcare and diagnostics companies and spent over a decade in M&A and corporate development roles at Becton Dickinson.
Board
EL
Erik LiumBoard director
WD
Westley DuprayBoard director
MH
Michael Hennessy Jr.Board director
MH
Molly HarperBoard director
PR
Paul RomaBoard director
Investors · 6
Also in the syndicate · 4
Eventide Asset ManagementleadGenHenn Capital VentureLabcorpQuest Diagnostics
Funding
SEC filings, press & company announcements$32M disclosed across 2 of 3 rounds · 2022–2025
- Undisclosed amountSeries A PreferredJan 2022Source ↗
▶$11.2MraisedJun 2025 · 9 investors · Other Health CareRule 506(b)
▶$11.2MraisedJun 2025 · 9 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Erik LiumDirector
- Westley DuprayDirector
- Michael Hennessy Jr.Director
- Paul RomaDirector
- Molly HarperDirector
- Eric ConverseExecutive Officer, Director
- Edward Joseph SitarExecutive Officer
- Offering amount
- $15M
- Amount sold
- $11.2M
- First sale
- May 2025
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$20.7MraisedApr 2024 · 10 investors · Other Health CareRule 506(b)
▶$20.7MraisedApr 2024 · 10 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Erik LiumDirector
- Eric ConverseDirector
- Wayne BrinsterExecutive Officer, Director
- Molly HarperDirector
- Westley DuprayDirector
- Offering amount
- $28.2M
- Amount sold
- $20.7M
- Sales commissions
- $800K
- Placement agents
- Aquilo Partners, L.P.
- First sale
- Feb 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlapCareDx8 shared keywordsCareDx provides innovative solutions and diagnostic tools for transplant patients throughout their pre- and post-transplant journey to improve outcomes and equity in organ transplantation.
PreciseMDX7 shared keywordsPreciseMDX offers an AI-driven platform for clinical and diagnostic laboratories that digitizes and automates lab order intake, converting handwritten requisitions, insurance cards, and IDs into structured data. It handles order management, verifies physician signatures, cross-maps lab codes, and provides analytics to reduce manual data entry and errors.
Itnonline6 shared keywordsImaging Technology News is a trade publication that reaches over 34,000 radiology, radiation oncology, women's health, and nuclear medicine professionals with editorial content and product comparison tools. The publication serves as a primary resource for healthcare technology purchasing decisions within medical imaging specialties.
Predictive Oncology5 shared keywordsPredictive Oncology develops drug discovery solutions for biopharma companies that combine artificial intelligence with a proprietary biobank of over 150,000 tumor samples to accelerate oncology drug development and improve therapeutic outcomes for cancer patients.
Precision5 shared keywordsPrecision is an AI platform paired with operators who build, train, and run AI agents across a company's marketing, delivery, support, operations, and finance functions. It targets professional, recurring-revenue businesses of 10-50 people (consultancies, coaches, agencies, recruiters, and software companies), installing and managing agents for them rather than leaving setup to DIY.
Companies competing with PreciseDx for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does PreciseDx do?
- PreciseDx develops molecular pathology diagnostic tools for cancer care, combining anatomical pathology with molecular and systems biology to enable precise diagnosis and treatment planning. The company's flagship product serves pathologists and oncologists seeking data-driven insights for patient risk stratification and personalized cancer care.
- Who founded PreciseDx?
- PreciseDx was founded by Dr. Carlos Cordon-Cardo in 2020.
- Who are PreciseDx's investors?
- PreciseDx's investors include Merck Global Health Innovation Fund, Philips Ventures.
- How much funding has PreciseDx raised?
- PreciseDx has disclosed $32M raised across 2 of its 3 known rounds.
- Where is PreciseDx headquartered?
- PreciseDx is headquartered in New York, US.